Previous 10 | Next 10 |
UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, today announced that the Centers for Medicare & Medicaid Services (CMS) has established a permanent and produc...
UroGen Pharma Ltd. (Nasdaq:URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, today announced that it will present at the following virtual conferences in November: Stifel 2020 Virtual He...
Image source: The Motley Fool. UroGen Pharma Ltd. (NASDAQ: URGN) Q3 2020 Earnings Call Nov 9, 2020 , 8:30 a.m. ET Operator Continue reading For further details see: UroGen Pharma Ltd. (URGN) Q3 2020 Earnings Call Transcript
UroGen Pharma Ltd (URGN) Q3 2020 Earnings Conference Call November 09, 2020 8:30 AM ET Company Participants Sara Sherman – Head of Investor Relations Liz Barrett – President and Chief Executive Officer Mark Schoenberg – Chief Medical Officer Jeff Bova – Chief Comme...
UroGen Pharma (URGN): Q3 GAAP EPS of -$1.31 beats by $0.15.Revenue of $3.46M beats by $0.12M.Press Release For further details see: UroGen Pharma EPS beats by $0.15, beats on revenue
Top-line Results from UGN-102 OPTIMA II Phase 2b Trial Expected by Year End 2020; On Track to Initiate Phase 3 ATLAS Trial by Year End Achieved Jelmyto ® Net Product Revenue of $3.5 Million in First Full Quarter of Commercialization Management Team Expanded to...
Conference Call and Webcast Scheduled for Monday, November 9, 2020 at 8:30 AM ET UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, today announced that ...
UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases because patients deserve better options, today announced that it will present at the following virtual conferences in September: H.C. W...
UroGen ( URGN +4.0% ) appointed three new executives to the company's Executive Leadership Team (ELT). More news on: UroGen Pharma Ltd., Healthcare stocks news, Stocks on the move Read more ...
BeiGene signs deal with Singlomics for neutralizing COVID-19 antibodies BeiGene Ltd. ( BGNE ) announced that it has inked a new deal with Singlomics Biopharmaceuticals Co. for developing, manufacturing and commercializing various anti-COVID-19 antibodies, including DXP-593 and DXP-604. U...
News, Short Squeeze, Breakout and More Instantly...
2024-07-15 04:14:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-25 07:34:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the pricing of an underwritten public offering of 5,000,000 ordinary shares at a price to the public of $17.50 per ord...